uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.…
uniQure CEO Defends Huntington’s Therapy Data, Sees Opportunity Ahead of FDA Decision
uniQure (NASDAQ: QURE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 221 employees.
The shares were at 19.35 USD on 20 November 2026, down 37.3% over 52 weeks. Its 52-week range is 8.730 USD to 51.20 USD: the price is 62.2% below the high and 121.6% above the low.
Its market capitalisation is 1.36B USD.
uniQure reports return on equity of -100.0% and revenue up 40.4% year over year.
It holds more cash than debt, a net cash position of 108.82M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 58.18 USD is 200.7% above the current price. The next earnings report is expected on 2 March 2027.